PDCD1 and tuberculosis: As tuberculosis research has uncovered, there are many factors that can influence the efficacy of immunotherapies, including antigen availability during disease progression and the fact that PD-1 may not be an exhaustion-specific marker that is useful for efficient checkpoint inhibition.